Amicus Therapeutics Stock (NASDAQ:FOLD), Trade Ideas

Amicus Therapeutics

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

BMBL

BROG

EDIT

FOLD

NVGS

STEM

U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session.

Nike, OPKO Health And Other Big Stocks Moving Higher In Friday&#39;s Pre-Market Session

Biotech

Health Care

General

The FDA has approved Amicus Therapeutics&#39; (NASDAQ: FOLD) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease.

Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease

The FDA approved Chiesi Group and Protalix BioTherapeutics Inc&#39;s (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult 

Fabry Disease Treatment Showdown: Protalix Bio&#39;s Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics

Amicus Therapeutics Inc

JP Morgan analyst Anupam Rama maintains Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Overweight and lowers the price target from $21 to $19.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Amicus Therapeutics, Lowers Price Target to $19

Cantor Fitzgerald analyst Kristen Kluska reiterates Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Overweight and maintains $22 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Amicus Therapeutics, Maintains $22 Price Target

Guidance

Amicus Therapeutics Projects 2024 Galafold Revenue Growth Of 11-16% At CER, Anticipates Full-Year Non-GAAP Profitability In 2024

Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) reported quarterly Adj earnings of $0.01 per share which beat the analyst consensus estimate of $(0.06) by 116.67 percent.&nbsp; The company reported quarterly sales of $115.08 million which beat the analyst consensus estimate of $114.33 million by 0.65 percent. This is a 30.63 percent increase over sales of $88.10 million the same period last year.

Earnings

Amicus Therapeutics Q4 Adj EPS $0.01 Beats $(0.06) Estimate, Sales $115.08M Beat $114.33M Estimate

Amicus Therapeutics Says It Received 2024 New Treatment Award For Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) At 20th Annual WORLDSymposium

Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "Last year was an incredible year for Amicus highlighted by the continued double-digit growth of Galafold sales and the global regulatory approvals of our second commercial therapy, which is off to a fantastic launch. We expect 2024 to be a truly transformative year as we continue to drive significant revenue growth by treating an increasing number of Fabry patients globally, executing on the global launches of Pombiliti and Opfolda, which we believe has the potential to become the standard of care in a &gt;$1B market today, and delivering our first full year of non-GAAP profitability. We look forward to reporting on our progress throughout this year as we further our mission for people living with rare diseases."
Amicus is focused on the following four key strategic priorities in 2024:
<ul>
<li>Delivering double-digit Galafold revenue growth (11-16% at CER)</li>
<li>Ensuring the successful global launches of Pombiliti + Opfolda</li>
<li>Advancing ongoing studies to support medical and scientific leadership in Fabry and Pompe diseases</li>
<li>Achieving full year non-GAAP profitability2</li>
</ul>
Mr. Campbell will discuss the Amicus corporate objectives and key milestones in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 2:15 p.m. PT. A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate website at <a href="https://www.globenewswire.com/Tracker?data=1BPuY0ki7w3ZawZ9jEuRbp13Xy0XDZgMKqGRHnKGMC-IeykctKSNAPwCE2CTx56qpCAjiaCanpywiArAWHODEKonekg9RJ9QNiagmYIJOS0o_1LXsWnDXM5ru9SpwXsA">http://ir.amicusrx.com/events.cfm</a>, and will be archived for 90 days.
1 In order to illustrate underlying performance, Amicus discusses its results in terms of constant exchange rate (CER) growth. This represents growth calculated as if the exchange rates had remained unchanged from those used in the comparative period. Full-year 2024 Galafold revenue guidance utilizes actual exchange rate as of December 31, 2023. 2 Non-GAAP Net Income defined as GAAP Net Income excluding the impact of share-based compensation expense, changes in fair value of contingent consideration, loss on impairment of assets, depreciation and amortization, acquisition related income (expense), loss on extinguishment of debt, loss on impairment of assets, restructuring charges, and income taxes.

Amicus Therapeutics Reports Preliminary 2023 Revenue And Provides 2024 Strategic Outlook; Q4 Revenue ~$115.1M Vs $112.25M Est.; Sees FY23 Revenue Of ~$399.4M Vs $396.45M Est.; Co Sees FY24 As First Full Year Of Achieving Non-GAAP Profitability

Analysts have provided the following ratings for Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) within the last quarter: 
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the last quarter, Amicus Therapeutics received 12-month price targets from 4 analysts. The average target price is $17.0, with a high estimate of $20.00 and a low estimate of $14.00.
Learn about 4 analysts' views on Amicus Therapeutics over the past 3 months. Increased bullish ratings reflect positive sentiment, while increased bearish ratings suggest a negative outlook.
<img src="https://www.benzinga.com/files/images/story/2023/1702998103_0.png" alt="price target chart" />
This average price target has increased by 11.48% over the past month.
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
Delve into the insights of financial experts and analysts as we provide a comprehensive breakdown of their recent evaluations for Amicus Therapeutics. Our Ratings Table below offers a detailed overview of the decisions made by key analysts, their current ratings, and price targets. Understanding how these experts perceive the company can yield valuable insights into potential market trends and investor sentiment.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Andrew Galler</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Andrew Galler</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Amicus Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Amicus Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Amicus Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Amicus Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FOLD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amicus Therapeutics analyst ratings.</a>
<h2>Discovering Amicus Therapeutics: A Closer Look</h2>
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
<h3>Unraveling the Financial Story of Amicus Therapeutics</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Amicus Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 26.7%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Amicus Therapeutics's net margin excels beyond industry benchmarks, reaching -20.85%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Amicus Therapeutics's ROE excels beyond industry benchmarks, reaching -17.63%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Amicus Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -2.89%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.41, caution is advised due to increased financial risk.
<h1>The Basics of Analyst Ratings</h1>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 4 Takes On Amicus Therapeutics

Morgan Stanley analyst Jeffrey Hung upgrades Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) from Equal-Weight to Overweight and raises the price target from $15 to $20.

Upgrades

Morgan Stanley Upgrades Amicus Therapeutics to Overweight, Raises Price Target to $20

Management

Amicus Therapeutics' John Crowley, Executive Chairman, Will Step Down, Effective March 4, 2024, Michael Raab, Lead Independent Director, Will Become The Chairman

Morgan Stanley analyst Andrew Galler maintains Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Equal-Weight and raises the price target from $14 to $15.

Morgan Stanley Maintains Equal-Weight on Amicus Therapeutics, Raises Price Target to $15

Amicus Therapeutics Is On-Track To Achieve Non-GAAP Profitability In Q4 2023

For FY23, Amicus Therapeutics Is Increasing Galafold Revenue Growth Guidance To Between 16 And 18% At CER

Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 41.67 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $103.50 million which beat the analyst consensus estimate of $101.36 million by 2.11 percent. This is a 26.70 percent increase over sales of $81.69 million the same period last year.

Amicus Therapeutics Q3 EPS $(0.07) Beats $(0.08) Estimate, Sales $103.50M Beat $101.36M Estimate

Morgan Stanley analyst Andrew Galler maintains Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Equal-Weight and lowers the price target from $15 to $14.

Morgan Stanley Maintains Equal-Weight on Amicus Therapeutics, Lowers Price Target to $14

Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule &nbsp;
Blackstone to also Purchase $30M of Amicus Common Stock
PRINCETON, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>), a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases, today announced that it has entered into a definitive agreement for a $430 million financing collaboration with funds managed by Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>). As part of the collaboration, Blackstone Life Sciences and Blackstone Credit have agreed to provide Amicus with a $400 million senior secured term loan facilitating a refinancing of existing debt and a $30 million strategic investment in Amicus's common stock. The financing collaboration allows Amicus to grow revenues and move toward profitability while delivering on its mission for patients and its vision of being one of the leading biotechnology companies focused on rare diseases.
Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, stated: "This new financing with Blackstone strengthens our balance sheet and financial profile by reducing the interest rate versus our current debt, pushing out the amortization schedule and extending the amortization period. This strategic investment demonstrates Blackstone's commitment to Amicus' future and belief in the strong growth potential of Galafold and Pombiliti&#x2122; + Opfolda&#x2122; as we continue on our mission to develop medicines for people living with rare diseases."
Key features of this transaction include:
<ul>
<li>$400M senior secured term loan facility; interest rate at adjusted Term SOFR plus 6.25%, subject to a 2.50% floor on Term SOFR</li>
<li>$30M investment in Amicus common stock</li>
<li>Requires interest-only payments until late 2026 and matures in October 2029</li>
<li>The full amount of the loan and equity purchase will be available and fully drawn at the initial funding</li>
<li>The proceeds will be used to refinance Amicus's existing debt and fund ongoing operations &nbsp;</li>
</ul>
Commenting on the arrangement, Craig Shepherd, Senior Managing Director with Blackstone Life Sciences and Brad Colman, Senior Managing Director with Blackstone Credit said: "Blackstone aims to provide customized financing solutions for the world's leading biotech and pharma companies across therapeutic areas to support mission critical scientific innovation. We are excited to collaborate with Amicus and provide capital to advance their mission of bringing important new medicines to people living with rare diseases around the world."
Simon Harford, Amicus Chief Financial Officer, added: "Securing this financing with Blackstone as we launch Pombiliti&#x2122; + Opfolda&#x2122; around the world, allows us to better align our borrowing with anticipated cash flows while at the same time enhancing our ability to maximize access to our therapies for people living with rare diseases."
Subject to completion of customary conditions, the loan is expected to be funded and the equity investment is expected to close on October 5, 2023.

Financing

Contracts

Amicus Therapeutics And Blackstone Enter Into $430M Strategic Financing Collaboration; Blackstone To Also Purchase $30M Of Amicus Common Stock

JP Morgan analyst Anupam Rama maintains Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Overweight and raises the price target from $17 to $19.

JP Morgan Maintains Overweight on Amicus Therapeutics, Raises Price Target to $19

U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today&rsquo;s pre-market trading session.
<ul>
<li>Brooge Energy Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brog#NASDAQ">BROG</a>) shares surged 23% to $6.64 in pre-market trading after gaining 7% on Thursday.</li>
<li>OPKO Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opk#NASDAQ">OPK</a>) shares climbed 12% to $1.68 in pre-market trading. OPKO&#39;s ModeX Therapeutics has been awarded a BARDA Contract to develop novel multispecific antibodies against viral infectious disease threats.</li>
<li>NIKE, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) shares gained 8.1% to $96.87 in pre-market trading after posting upbeat quarterly earnings.</li>
<li>Editas Medicine, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/edit#NASDAQ">EDIT</a>) shares rose 8% to $7.47 in pre-market trading. Stifel upgraded Editas Medicine from Hold to Buy and raised the price target from $9 to $17.</li>
<li>Amicus Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fold#NASDAQ">FOLD</a>) shares gained 7.2% to $12.71 in pre-market trading after falling around 8% on Thursday. The FDA approved Amicus Therapeutics&#39; Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease.</li>
<li>Navigator Holdings Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvgs#NYSE">NVGS</a>) shares climbed 5.7% to $15.72 in pre-market trading.</li>
<li>Bumble Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmbl#NASDAQ">BMBL</a>) shares gained 4.4% to $15.11 in pre-market trading.</li>
<li>Stem, Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/stem#NYSE">STEM</a>) shares rose 4.1% to $4.35 in pre-market trading after adding 3% on Thursday.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/09/34994025/investor-fear-eases-as-us-stocks-rise-following-economic-reports"> Investor Fear Eases As US Stocks Rise Following Economic Reports</a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session

The FDA has approved&nbsp;Amicus Therapeutics&#39;&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fold#NASDAQ">FOLD</a>) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease.
It&#39;s a disease in which the body can&#39;t make a protein that breaks down a complex sugar called glycogen for energy. Too much sugar builds up and damages muscles and organs.
This two-component therapy is indicated for adults living with late-onset Pompe disease (LOPD) weighing &ge;40 kg and who are not improving on their current&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/09/g34978580/amicus-therapeutics-announces-fda-approval-and-launch-of-new-treatment-for-pompe-disease" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">enzyme replacement therapy (ERT)</a>.
Pombiliti is a recombinant human GAA enzyme (rhGAA) naturally expressed with high levels of bis-M6P (Mannose 6-Phosphate), designed for increased uptake into muscle cells. Once in the cell, Pombiliti can be properly processed into its most active and mature form to break down glycogen.&nbsp;
Opfolda is an enzyme stabilizer designed to stabilize the enzyme in the blood.
The FDA approval was based on clinical data observed from the Phase 3 pivotal study (PROPEL), the only trial in LOPD to study ERT-experienced participants in a controlled setting.
Price Action:&nbsp;FOLD shares are down 6.65% at $12.03 on the last check Thursday.

Amicus Therapeutics Shares Resume Trade

Amicus Therapeutics, Inc. Shares To Resume Trade At 11:10 a.m. ET

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Amicus (FOLD – Research Report), with a price target of $20.00. Rit...

Buy Rating Affirmed for Amicus with Strong Growth and Promising Outlook

In a report released today, Gil Blum from Needham maintained a Hold rating on Amicus (FOLD – Research Report). The company's shares closed yesterda...

Needham Sticks to Its Hold Rating for Amicus (FOLD)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alignment Healthcare (ALHC – Research Report), TG Therapeutics (T...

Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), TG Therapeutics (TGTX) and Amicus (FOLD)

Amicus Therapeutics: Expect Improved Commercial Momentum In 2024

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on FOLD stock, giving a Buy rating on February 28. Joseph Schwartz has...

Buy Rating Affirmed: Amicus's Strong Product Launch and Growth Trajectory

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amicus (FOLD – Research Report), Xenon (XENE – Research Report) a...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Amicus (FOLD), Xenon (XENE) and Veeva Systems (VEEV)

The market has been down on Amicus Therapeutics, Inc. (FOLD)  stock recently. FOLD gets a Bearish score from InvestorsObserver Stock Sentiment Indicator. Amicus Therapeutics, Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on FOLD!See Full FOLD ReportWhat is Stock Sen

Is Amicus Therapeutics, Inc. (FOLD) a Stock to Watch After Losing -1.33% This Week?

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on FOLD stock, giving a Buy rating on February 28. Anupam Rama's rating is base...

Amicus's Growth Trajectory Reinforces Buy Rating Amid Strong Product Prospects and Revenue Milestones

Amicus Therapeutics, Inc. (FOLD) stock has fallen 0.51% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. Amicus Therapeutics, Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on FOLD!See Full FOLD ReportWhat is Stock Sentiment?Wh

Where Will Amicus Therapeutics, Inc. (FOLD) Stock Go Next After It Has Fallen 0.51% in a Week?

As more rare disease therapies launch, their prices are rising

ALHC

AMGN

ARCT

BIIB

INBX

RARE

RHHBY

SRPT

TGTX

TVTX

VEEV

XENE

Press Releases

Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO

Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook

Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024

Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™